Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Abemaciclib in Brain Metastases from HR+ Breast Cancer, NSCLC, or Melanoma
2014-004010-28Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in brain metastases, breast cancer, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Eli Lilly and Company. Primary endpoint: Objective Intracranial Response Rate (OIRR). Started Jan 2015; status: completed.
02
Drugs
abemaciclib
03
Conditions
brain metastasesbreast cancernon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on 2014-004010-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004010-28.